Parabilis Medicines (PBLS) news
Recent news
Lycia Therapeutics Inc. files for IPO
Lycia Therapeutics Inc., a clinical-stage biotechnology company focused on the development of novel therapeutics for autoimmune, inflammatory, and allergic diseases, has recently made notable progress in its financing and development activities. The company, which has been backed by several…
AInvest Wire · 7d agoHBM Healthcare Investments posts solid half-year result – expected profit of CHF 177 million
HBM Healthcare Investments AG has reported a strong half-year performance, with an expected profit of CHF 177 million for the period. This result reflects continued growth and successful investment strategies across its portfolio companies. The firm has recently made significant investments in…
AInvest Wire · Oct 1, 2026Regeneron exec says co eligible to receive $1 bln in potential milestone payment with the start of the first late-stage trial as part of the deal -Conf call
Regeneron Pharmaceuticals, Inc. (REGN) is positioned to receive up to $1 billion in potential milestone payments as part of its expanded collaboration with Sanofi, according to remarks made during a conference call. The companies announced the expansion of their longstanding antibody collaboration,…
AInvest Wire · Oct 1, 2026Alphabet Inc reports share stake of 4.92 mln common shares in Parabilis Medicines
Alphabet Inc. has reported a shareholding of 4.92 million common shares in Parabilis Medicines, according to recent filings. This stake represents a notable investment in the clinical-stage biopharmaceutical company, which recently completed a record-breaking $670 million initial public offering .…
AInvest Wire · Aug 7, 2026Parablis Medicines, Inc: BofA Global Research initiates coverage with buy rating and price objective $45.00
Bank of America Global Research has initiated coverage on Parabilis Medicines, Inc. (PBLS) with a "Buy" rating and a price objective of $45.00 per share. The move reflects the firm’s confidence in the company’s growth potential and strategic positioning within the biopharmaceutical sector. BofA’s…
AInvest Wire · Jul 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.